Skip to main content
ScholarsBetaWeill Cornell Medicine

Publications

26 publications

Funding

2 grants
Completed grants (2)
  • MPI
    AIDS Malignancy Consortium (AMC)
    National Cancer Institute · 2022–2025 · via EMMES Corporation
    UM1CA121947-15
  • PI
    A Phase I/II study of durvalumab, CD73 antibody Oleclumab, and non-ablative radiation for treatment of advanced EGFR mutated non-small cell lung cancers
    Conquer Cancer Foundation of the American Society of Clinical Oncology · 2021–2023
    ASCO 211193-01

Clinical research

17 studies

Active

6 studies
  • PI
    Compassionate Use of Out of Specification Lifileucel (LN-144) for Treatment of Melanoma in Patient V-P
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
  • PI
    Compassionate Use of Out of Specification Lifileucel (LN-144) for Treatment of Melanoma in Patient V-P-R
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
  • PI
    A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
    PHASE1; PHASE2 · Iovance Biotherapeutics, Inc · OPEN TO ACCRUAL (as of 2026)
    Unresectable Melanoma; Metastatic Melanoma; Stage III Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
    NCT05361174
  • PI
    Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
    Iovance Biotherapeutics, Inc · OPEN TO ACCRUAL (as of 2025)
    Unresectable Melanoma; Metastatic Melanoma
    NCT05398640
  • PI
    Retrospective Real World Evidence of Patients Infused with Commercially Released AMTAGVI (lifileucel) for Unresectable or Metastatic Melanoma
    Iovance Biotherapeutics, Inc · OPEN TO ACCRUAL (as of 2025)
  • PI
    Use of Blood, Tumor Tissue, and Tumor Infiltrating Lymphocyte Biospecimens for Immune Cell Profiling and Research
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
Completed & closed trials (11)
  • PI
    Compassionate Use of Out of Specification Lifileucel (LN-144) for Treatment of Melanoma in Patient M-B
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2026)
  • PI
    Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
    PHASE2; PHASE3 · ECOG-ACRIN Cancer Research Group · CLOSED TO ACCRUAL (as of 2026)
    Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7
    NCT02339571
  • PI
    An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors
    PHASE1 · IDEAYA Biosciences · IRB STUDY CLOSURE (as of 2025)
    Solid Tumor
    NCT04794699
  • PI
    Compassionate Use of Out of Specification Lifileucel (LN-144) for Treatment of Melanoma in Patient R-T
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
  • PI
    A Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma
    PHASE2 · National Cancer Institute · CLOSED TO ACCRUAL (as of 2025)
    Skin Kaposi Sarcoma
    NCT04577755
  • PI
    Phase II Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
    PHASE2 · Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
    Thymic Carcinoma
    NCT04925947
  • PI
    Compassionate Use of TAC-001 for Treatment of Melanoma in Patient L-P
    Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)
  • PI
    Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Platinum Based Chemotherapy (TROPION-Lung05)
    PHASE2 · Daiichi Sankyo, Inc. · IRB STUDY CLOSURE (as of 2023)
    Non-small Cell Lung Cancer
    NCT04484142
  • PI
    Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
    PHASE1; PHASE2 · Jounce Therapeutics, Inc. · IRB STUDY CLOSURE (as of 2023)
    Cancer
    NCT04669899
  • PI
    A Multicenter, Non-randomized, Open-label Phase 1b Study to Determine the Maximum Tolerated and Recommended Phase 2 Dose of the ATR Inhibitor Elimusertib in Combination With Pembrolizumab and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Participants With Advanced Solid Tumors
    PHASE1 · Bayer Healthcare Pharmaceuticals · IRB STUDY CLOSURE (as of 2023)
    Advanced Solid Tumors
    NCT04095273
  • PI
    A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma
    PHASE2 · Jiangsu Alphamab Biopharmaceuticals · IRB STUDY CLOSURE (as of 2023)
    Thymic Carcinoma
    NCT04469725

External relationships

Advisory/Scientific Board Member

Iovance Biotherapeutics, Inc